Optimizing Transitions from Hospital to Home: Best Practices for Reducing Readmissions in Heart Failure




Although modern medicine has substantially improved outcomes in patients with heart failure (HF), the associated morbidity and mortality remain unacceptably high. Patients hospitalized with HF-related issues show poor outcomes following discharge, with 1 out of 10 not surviving 3 months and nearly 1 out of 3 re-hospitalized within 1 year. Recently published guidelines from national and international organizations provide clear guidance on how to improve these outcomes, yet many recommendations are not followed. Guideline-directed medication therapy (GDMT) is essential to ensuring patients receive appropriate care. Clinicians must thoroughly understand how to diagnose and assess these patients because stages and functional classifications are necessary for determining management strategy. Up-to-date knowledge of medications and their places in GDMT is essential, as well as staying abreast of safety and efficacy data on recent FDA approvals. Two newly approved agents, sacubitril/valsartan and ivabradine, have been shown to improve outcomes in patients with HF, and clinicians will need to be educated about them. Lastly, ensuring effective transitions of care is paramount to ensuring optimal outcomes, and clinicians must be aware of barriers to care and strategies for overcoming these obstacles.


Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Gerald S. Berenson Endowed Chair
in Preventive Cardiology
Professor of Medicine
John W. Deming Department of Medicine
Tulane University School of Medicine
New Orleans, Louisiana


Release date: July 30, 2020
Expiration date: July 30, 2021
Estimated time to complete activity: 1.0 hour



This educational initiative has been designed for physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists who practice in hospital and internal medicine settings.


Upon completion of this educational activity, participants should be able to:

  • Apply diagnostic and assessment criteria to the effective management of patients with HF
  • Integrate current GDMT and recent clinical trial outcomes into the effective management of patients with HF
  • Develop a comprehensive GDMT approach to HF management in patients who have recently experienced an acute HF episode
  • Review proven strategies to achieve successful transitions of care in patients with HF

There are no fees for participating and receiving CME/CE credit for this activity. During the period of July 30, 2020 through July 30, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Pharmacists must check the CPE monitor for their credits within 60 days of the activity.




Physician Continuing Education

Accreditation Statement
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education designates this free live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


Global Education Group designates this free continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number – 0530-9999-20-076-H01-P.)

This is a knowledge-based activity.


Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This free educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or hms@integrityce.com.

For information about ACPE or ANCC accreditation of this activity, please contact Global at (303) 395-1782 or cme@globaleducationgroup.com.


Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10
Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.


Integrity Continuing Education and Global Education Group requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent COI they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education and Global Education Group for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following planners and managers (along with their spouses/life partners) reported no financial relationships nor relationships to products or devices with commercial interests related to the content of this CME activity: Lindsay Borvansky, Rachel Brown, PharmD, MPH, Ashley Cann, Andrea Funk, Donna Fausak, Liddy Knight, and Ashley Marostica, RN, MSN.


Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Consultant: Amgen, Boehringer Ingelheim, Eli Lilly, Janssen, Novartis, Quantum Genomics, Sanofi.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)


This CME activity is provided by Integrity Continuing Education.
This CEU/CNE activity is jointly provided by Global Education Group and Integrity Continuing Education.


This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.


Continue to Pretest